These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 26014752)

  • 1. Calcium-Channel Blockers Attenuate the Antiplatelet Effect of Clopidogrel.
    Gremmel T; Durstberger M; Eichelberger B; Koppensteiner R; Panzer S
    Cardiovasc Ther; 2015 Oct; 33(5):264-9. PubMed ID: 26014752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Antiplatelet Effect of Clopidogrel Decreases With Patient Age.
    Xhelili E; Eichelberger B; Kopp CW; Koppensteiner R; Panzer S; Gremmel T
    Angiology; 2016 Nov; 67(10):902-908. PubMed ID: 26861857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Heart; 2010 Feb; 96(3):186-9. PubMed ID: 19687016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: Differences between peripheral and coronary angioplasty.
    Gremmel T; Xhelili E; Steiner S; Koppensteiner R; Kopp CW; Panzer S
    Atherosclerosis; 2014 Jan; 232(1):119-24. PubMed ID: 24401225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel.
    Siller-Matula JM; Lang I; Christ G; Jilma B
    J Am Coll Cardiol; 2008 Nov; 52(19):1557-63. PubMed ID: 19007592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preserved thrombin-inducible platelet activation in thienopyridine-treated patients.
    Gremmel T; Kopp CW; Seidinger D; Koppensteiner R; Steiner S; Panzer S
    Eur J Clin Invest; 2013 Jul; 43(7):689-97. PubMed ID: 23611368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Transl Res; 2013 May; 161(5):421-9. PubMed ID: 23340049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prasugrel reduces agonists' inducible platelet activation and leukocyte-platelet interaction more efficiently than clopidogrel.
    Gremmel T; Eslam RB; Koppensteiner R; Lang IM; Panzer S
    Cardiovasc Ther; 2013 Oct; 31(5):e40-5. PubMed ID: 23311679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response.
    Harmsze AM; Robijns K; van Werkum JW; Breet NJ; Hackeng CM; Ten Berg JM; Ruven HJ; Klungel OH; de Boer A; Deneer VH
    Thromb Haemost; 2010 May; 103(5):920-5. PubMed ID: 20352154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Aggregometry with Flow Cytometry for the Assessment of Agonists´-Induced Platelet Reactivity in Patients on Dual Antiplatelet Therapy.
    Gremmel T; Koppensteiner R; Panzer S
    PLoS One; 2015; 10(6):e0129666. PubMed ID: 26058047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance.
    Lev EI; Patel RT; Maresh KJ; Guthikonda S; Granada J; DeLao T; Bray PF; Kleiman NS
    J Am Coll Cardiol; 2006 Jan; 47(1):27-33. PubMed ID: 16386660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Barrera-Ramirez C; Sabaté M; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Macaya C
    Thromb Res; 2005; 115(1-2):101-8. PubMed ID: 15567460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prasugrel 5 mg inhibits platelet P-selectin and GPIIb-IIIa expression in very elderly and non elderly: results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients.
    Wagner H; Lood C; Borna C; Gidlöf O; Truedsson L; Brown P; Zhou C; Winters K; Jakubowski JA; Erlinge D
    J Thromb Thrombolysis; 2016 Oct; 42(3):369-75. PubMed ID: 27165280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Alfonso F; Sabaté M; Fernández C; Stranieri C; Trabetti E; Pignatti PF; Macaya C
    Blood Coagul Fibrinolysis; 2004 Jan; 15(1):89-93. PubMed ID: 15166949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel.
    Bliden KP; Dichiara J; Lawal L; Singla A; Antonino MJ; Baker BA; Bailey WL; Tantry US; Gurbel PA
    J Am Coll Cardiol; 2008 Aug; 52(7):531-3. PubMed ID: 18687246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Macaya C
    Am J Cardiol; 2006 Jan; 97(1):38-43. PubMed ID: 16377281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
    Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM
    Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of platelet surface receptors and early changes in platelet function in patients with STEMI treated with abciximab and clopidogrel versus clopidogrel alone.
    Konopka A; Spychalska J; Sitkiewicz D; Zdebska E; Pilichowska I; Piotrowski W; Stepińska J
    Am J Cardiovasc Drugs; 2007; 7(6):433-9. PubMed ID: 18076210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Hernández-Antolín R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Macaya C
    J Invasive Cardiol; 2004 Jun; 16(6):325-9. PubMed ID: 15156004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy.
    Gremmel T; Müller M; Steiner S; Seidinger D; Koppensteiner R; Kopp CW; Panzer S
    Nephrol Dial Transplant; 2013 Aug; 28(8):2116-22. PubMed ID: 23729489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.